top of page

EC approves MabThera for chronic lymphocytic leukaemia

The European Commission (EC) has approved the subcutaneous formulation of Roche’s MabThera (rituximab) for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page